Kamada

Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the drug products in Israel, which are manufactured by third parties. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kamada reports robust earnings, eyes global expansion and clinical milestones

Kamada's strong financial performance, strategic acquisitions, and global expansion efforts position the company for continued growth and market success.
While facing challenges in maintaining growth momentum and operational efficiency, Kamada's focus on innovation and market expansion presents significant opportunities for future development.
Investors should monitor Kamada's progress in clinical trials, product diversification, and international market penetration to assess the company's long-term growth potential and market positioning.

Kamada secures $60M investment, targets 35% revenue growth in 2023

Kamada's Q1 2023 performance showed revenue and EBITDA growth, supported by strategic investments and regulatory approvals. While facing rising expenses and financial challenges, the company aims for significant revenue growth in 2023 through market expansion and trial acceleration.

Kamada (KMDA) reports strong Q2 earnings and secures $60M investment

Kamada (KMDA) delivered robust financial results in Q2 2023, with significant revenue growth and positive EBITDA performance.
The company's strategic investments, diverse product pipeline, and regulatory progress underscore its potential for future growth and market expansion.
Stable cash position, operational efficiency, and ongoing clinical advancements position Kamada favorably in the biopharmaceutical industry.
Overall, Kamada's Q2 performance and future outlook reflect a promising trajectory for sustained growth and value creation for shareholders.

Kamada reports robust Q3 earnings, eyes growth through clinical trials

Kamada's Q3 2023 earnings call highlighted strong financial performance, debt-free status, and strategic initiatives for future growth. The company's focus on product development, clinical trials, and board expertise positions it well for continued success and profitability.

Kamada reports robust 2023 earnings, eyes growth through strategic initiatives

Kamada's strong financial performance in 2023 and positive outlook for 2024 underscore the company's growth trajectory and market positioning.
While facing challenges such as rising operating expenses, Kamada's focus on innovation, market expansion, and strategic partnerships presents opportunities for sustained growth.
Maintaining a robust balance sheet and advancing key clinical trials reflect Kamada's commitment to financial stability, product development, and long-term value creation.

Kamada doubles profitability in Q1 2024, eyes revenue growth

Kamada delivered robust financial performance in Q1 2024, with doubled profitability and revenue growth driven by key products. The company's strategic initiatives, including product launches and clinical trial progress, position it well for future success. While facing cost pressures, Kamada's strong cash position and focus on innovation present opportunities for sustained growth.

Kamada excels in Q2, eyes global expansion and clinical milestones

Kamada's strong financial performance in Q2 2024 and the first half of the year, coupled with reaffirmed full-year guidance, reflect a positive growth trajectory and financial stability.
The company's strategic focus on organic growth, M&A activities, and clinical trials positions it well to capitalize on market opportunities and drive future revenue expansion.
While challenges such as dividend policy, regulatory timelines, and market competition exist, Kamada's proactive approach to business development and global partnerships underscores its commitment to sustained growth and innovation.

Kamada reports strong Q3 earnings, eyes growth in clinical trials

Kamada's Q3 2024 earnings call highlighted robust financial performance, increased guidance, and strategic initiatives driving growth and market expansion.
With a strong balance sheet, ongoing clinical trials, and expansion plans, Kamada is well-positioned to capitalize on market opportunities and sustain growth momentum.
While challenges such as market competition and integration risks exist, Kamada's proactive approach to innovation, partnerships, and operational efficiency bodes well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eli Lilly

Eli Lilly and Kamada are two of the most intriguing companies working on this part of the COVID-19 problem.

2 Coronavirus Treatment Stocks to Buy Right Now

Kamada Ltd. (NASDAQ: KMDA) took a big step in the fight against COVID-19 on Tuesday when the biopharmaceutical company announced initial interim results from its ongoing midstage coronavirus study of its treatment of COVID-19 patients with pneumonia.

Are More Positive Results on the Way for Kamada’s COVID-19 Pneumonia Treatment?

REHOVOT, Israel, Sept.  08, 2020  (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced the completion of enrollment and initial interim results from its ongoing Phase 1/2 open-label, single-arm, multi-center clinical trial in Israel of the Company’s anti-SARS-CoV-2 plasma-derived hyperimmune immunoglobulin (IgG) product as a potential treatment for coronavirus disease (COVID-19).

Kamada Announces Completion of Enrollment and Initial Interim Results from its Phase 1/2 Clinical Trial in Israel of its Plasma-Derived Hyperimmune Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19)

Cerus

T2 Biosystems

Convalescent plasma stocks moved northward following FDA's emergency plasma authorization for COVID-19 treatment. Here're three of them that should be on your watch list -

3 Plasma Stocks to Win Big on FDA's Convalescent EUA

ADMA Biologics

Emergent BioSolutions

Convalescent plasma holds promise for treating COVID-19, but it's still unproven.

What You Need to Know About the "Breakthrough" Coronavirus Therapy Heralded by President Trump

Grifols, S.A.

Liminal BioSciences

Sonnet BioTherapeutics

ThermoGenesis Holdings, Inc

Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use of investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients.

These Plasma Stocks Are Surging After FDA's Convalescent EUA

The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients as part of the agency’s ongoing efforts to fight COVID-19.

FDA Issues Emergency Use Of Convalescent Plasma For COVID–19 Treatment

REHOVOT, Israel and FORT LEE, N.J., Aug.  19, 2020  (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA) and Kedrion Biopharma, two leading biopharmaceutical companies specialized in plasma-derived protein therapeutics, today announced results from a U.S. post-marketing pediatric trial of KEDRAB® (Rabies Immune Globulin [Human]). The study represents the first and only trial of a currently available human rabies  immune globulin (HRIG) conducted in children in the U.S. to date. The results have been submitted to the U.S. Food and Drug Administration for review and inclusion as pediatric data in the KEDRAB full prescribing information. KEDRAB is a human rabies immunoglobulin (HRIG) indicated for passive, transient post-exposure prophylaxis (PEP) treatment of rabies infection, when given promptly after contact with a rabid or possibly rabid animal.

Kamada and Kedrion Biopharma Announce Results of First and Only U.S. Post-Marketing Pediatric Trial of a Human Rabies Immune Globulin (HRIG); The Study Met Its Primary Objective

Kamada's (KMDA) CEO Amir London on Q2 2020 Results - Earnings Call Transcript

Kamada (KMDA) delivered earnings and revenue surprises of -25.00% and -4.40%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Kamada (KMDA) Q2 Earnings and Revenues Lag Estimates

REHOVOT, Israel, Aug.  12, 2020  (GLOBE NEWSWIRE) --  Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced changes to the composition of its Board of Directors. Lilach Asher Topilsky, a Director on the Company’s Board and a Senior Partner at FIMI Opportunity Funds, the leading private equity investor in Israel and Kamada’s largest shareholder, has been appointed Chairman of the Board. The current Chairman, Leon Recanati, will remain on the Board as a Director. In addition, Ari Shamiss MD, MPA, a veteran hospital senior executive, has joined as a new Director, to serve until the Company's next annual meeting of shareholders, at which he will stand for election by the shareholders. The Company’s Board now consists of nine members. 

Kamada Announces Changes to its Board of Directors

Shares of Kamada (NASDAQ:KMDA) moved lower by 2.5% in pre-market trading after the company reported Q2 results.

Recap: Kamada Q2 Earnings

REHOVOT, Israel, Aug.  12, 2020  (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and six months ended June 30, 2020.

Kamada Reports Second Quarter and First Six Months of 2020 Financial Results, Recent Corporate Achievements and Strong Cash Position  

REHOVOT, Israel, Aug.  10, 2020  (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that the first patient has been recruited to the Phase 1/2 clinical trial of its anti-SARS-CoV-2 plasma-derived immunoglobulin (IgG) product as a potential treatment for coronavirus disease (COVID-19) in Israel.

Kamada Announces Enrollment of First Patient in its Phase 1/2 Clinical Trial of its Plasma-Derived Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19) in Israel

REHOVOT, Israel, Aug.  05, 2020  (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the second quarter ended June 30, 2020, prior to the open of the U.S. financial markets on Wednesday, August 12, 2020.

Kamada to Announce Second Quarter Ended June 30, 2020 Financial Results and Host Conference Call on August 12, 2020

Chanticleer Hlds

Plasma stocks were trading higher Friday after President Donald Trump encouraged Americans who have recovered from COVID-19 to donate their convalescent blood plasma as a treatment for the virus.

Plasma Stocks Move After Trump Roundtable On COVID-19

Kamada might be the least well-known biotech company working on a COVID-19 treatment right now.

The 1 Promising Coronavirus Stock No One Knows About Yet

Kamada: Under-The-Radar COVID-19 Therapy Play With Downside Protection And Margin Of Safety

Kamada (KMDA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Kamada (KMDA) Looks Good: Stock Adds 5.7% in Session

REHOVOT, Israel, June  17, 2020  (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today provided an update on its development of a plasma-derived immunoglobulin (IgG) product for Coronavirus Disease (COVID-19).

Kamada Announces Availability of its Plasma-Derived Hyperimmune IgG Therapy for Coronavirus Disease (COVID-19) for Compassionate Use Treatment in Israel

Kamada (KMDA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Kamada (KMDA) Stock Stands Out in a Strong Industry

Kamada Ltd (KMDA) CEO Amir London on Q1 2020 Results - Earnings Call Transcript

Kamada (KMDA) delivered earnings and revenue surprises of 62.50% and 8.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Kamada (KMDA) Q1 Earnings and Revenues Top Estimates

Shares of Kamada (NASDAQ:KMDA) were flat in pre-market trading after the company reported Q1 results.

Recap: Kamada Q1 Earnings

RedHill Biopharma

Vir Biotechnology

Several drug/biotech companies are working on making new antibodies, drugs, and vaccines to prevent and treat COVID-19.

News for Kamada Stock (KMDA)